IFNAR2 — Interferon Alpha Receptor 2

IFNAR2 — Interferon Alpha Receptor 2

Introduction

IFNAR2 — Interferon Alpha Receptor 2

Introduction

The IFNAR2 gene (Interferon Alpha and Beta Receptor Subunit 2) encodes the signal-transducing component of the type I interferon (IFN-I) receptor, a crucial membrane protein that mediates cellular responses to interferons including IFN-alpha, IFN-beta, IFN-omega, and IFN-kappa. IFNAR2 plays a central role in the JAK-STAT signaling pathway, mediating the antiviral and immunomodulatory effects of type I interferons throughout the body. In the central nervous system (CNS), IFNAR2 is expressed in [neurons](/entities/neurons), [microglia](/cell-types/microglia-neuroinflammation), [astrocytes](/entities/astrocytes), and [oligodendrocytes](/entities/oligodendrocytes), where it regulates both protective antiviral responses and pathological neuroinflammatory cascades["@deweerd2011"].

Mounting evidence implicates dysregulated IFN-I signaling through IFNAR2 in the pathogenesis of neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) (AD) and [Parkinson's disease](/diseases/parkinsons-disease) (PD). Chronic activation of the IFN-I response in the brain contributes to synaptic dysfunction, microglial activation, and progressive neuronal loss. Consequently, IFNAR2 has emerged as a potential therapeutic target, with JAK inhibitors showing promise in preclinical models of neurodegeneration["@tay2012"][@dhareshwari2021].

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Interferon Alpha Receptor 2</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>IFNAR2</td></tr>
<tr><td><strong>Full Name</strong></td><td>Interferon Alpha and Beta Receptor Subunit 2</td></tr>
<tr><td><strong>Chromosome</strong></td><td>21q22.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[3455](https://www.ncbi.nlm.nih.gov/gene/3455)</td></tr>
<tr><td><strong>OMIM</strong></td><td>206550</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000159197</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P48551](https://www.uniprot.org/uniprot/P48551)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Systemic Lupus Erythematosus</td></tr>
</table>
</div>

Gene Structure and Protein Architecture

Genomic Organization

The IFNAR2 gene is located on chromosome 21q22.1 and spans approximately 40 kilobases. It consists of multiple exons that undergo alternative splicing to generate distinct protein isoforms with different signaling properties.

| Property | Value |
|----------|-------|
| Gene Symbol | IFNAR2 |
| Chromosomal Location | 21q22.1 |
| NCBI Gene ID | 3455 |
| Ensembl ID | ENSG00000159197 |
| UniProt | P48551 |
| RefSeq | NM_001034200 |

Protein Structure

The IFNAR2 protein (approximately 505 amino acids) contains several critical structural domains:

Unlike IFNAR1, which primarily serves as a ligand-binding subunit with limited intracellular signaling capacity, IFNAR2 contains the essential intracellular domain necessary for JAK-STAT pathway activation[@deweerd2011].

Normal Biological Functions

Type I Interferon Signaling Pathway

IFNAR2 is the central signal-transducing component of the type I interferon receptor. The canonical signaling cascade proceeds as follows:

This pathway mediates the antiviral, immunomodulatory, and antiproliferative effects of type I interferons throughout the body[@deweerd2011][@tay2012].

Soluble IFNAR2 Isoforms

IFNAR2 exists in both membrane-bound and soluble forms due to alternative splicing. The soluble isoform (sIFNAR2) lacks the transmembrane domain and is secreted as a naturally occurring antagonist that can neutralize type I interferons. This isoform has gained attention as a potential therapeutic agent for conditions characterized by excessive IFN-I signaling[@matic2023].

Expression Pattern in the Central Nervous System

Cellular Distribution

IFNAR2 is widely expressed in the CNS across multiple cell types:

• Neurons: High expression throughout the brain, particularly in hippocampal pyramidal neurons, cortical pyramidal neurons, and dopaminergic neurons in the substantia nigra
• Microglia: Express IFNAR2 at moderate levels; receptor engagement triggers inflammatory cytokine production
• Astrocytes: Display IFNAR2 expression; respond to IFN-I with increased chemokine secretion
• Oligodendrocytes: Lower expression; IFN-I signaling may affect myelination
• Endothelial Cells: Mediate blood-brain barrier responses to circulating interferons

Regional Expression

High expression is observed in:

• Hippocampus (CA1-CA3 regions, dentate gyrus)
• Cerebral cortex (all layers, particularly layer 5)
• Substantia nigra (dopaminergic neurons)
• Cerebellum (Purkinje cells)
• Hypothalamus
• Amygdala

Disease Associations

Alzheimer's Disease

IFNAR2 plays a significant role in AD pathogenesis through multiple mechanisms:

Chronic Neuroinflammation: Elevated IFN-α levels and increased IFN-stimulated gene expression have been documented in AD brain tissue. The IFN-I response drives microglial activation and complement cascade activation, leading to synaptic pruning and neuronal injury[@goldmann2015][@czirr2017].

Synaptic Dysfunction: Type I interferon signaling directly affects synaptic plasticity in the hippocampus. IFN-I exposure impairs long-term potentiation (LTP) and promotes long-term depression (LTD), correlating with memory deficits[@wen2017][@zhao2021].

Tau Pathology: Recent studies suggest a bidirectional relationship between IFN-I signaling and tau pathology. IFN-I exposure accelerates tau phosphorylation and aggregation, while tau pathology potentiates IFN-I responses, creating a feed-forward loop of neurodegeneration[@oxford2022].

Human Studies: Transcriptomic analysis of AD brain reveals robust activation of IFN-I response genes, with IFNAR2 expression correlating with disease severity. CSF levels of IFN-β are elevated in AD patients compared to controls[@roy2020].

Parkinson's Disease

IFNAR2 contributes to PD pathophysiology through neuroinflammatory mechanisms:

Microglial Activation: IFN-I signaling primes microglia, making them more responsive to subsequent inflammatory stimuli. This "primed" state leads to exaggerated pro-inflammatory cytokine release in response to α-synuclein pathology[@jiang2022].

Dopaminergic Neuron Vulnerability: IFNAR2-mediated signaling reduces the viability of dopaminergic neurons in vitro. The substantia nigra appears particularly susceptible to IFN-I-induced toxicity due to its relatively high IFNAR2 expression[@lin2019].

JAK Inhibition Protection: JAK inhibitors protect dopaminergic neurons from IFN-I-induced cell death in both cell culture and animal models of PD, supporting the therapeutic potential of targeting this pathway[@choi2021].

Multiple Sclerosis

IFNAR2 has complex and dual roles in MS:

Therapeutic Mechanism: IFN-β (a type I interferon) is used as a first-line treatment for MS. Its therapeutic effects are mediated through IFNAR2, which modulates immune cell function and reduces relapses. However, the response is variable and diminishes over time.

Pathogenic Role: In some contexts, IFN-I signaling contributes to disease progression through mechanisms similar to those observed in AD and PD[@main2018].

Systemic Lupus Erythematosus

IFNAR2 is central to SLE pathophysiology:

Genetic Associations: IFNAR2 polymorphisms are associated with increased SLE risk Pathogenic Mechanism: Chronic IFN-I activation drives autoantibody production and immune complex deposition Therapeutic Implications: Targeting IFNAR2 or its downstream signaling represents a promising therapeutic approach[@matic2023]

Molecular Mechanisms

JAK-STAT Signaling

The JAK-STAT pathway is the primary signaling cascade initiated by IFNAR2:

| Kinase | Role |
|--------|------|
| TYK2 | Associated with IFNAR1; phosphorylates STAT2 |
| JAK1 | Associated with IFNAR2; phosphorylates STAT1 |

| STAT | Function |
|------|----------|
| STAT1 | Forms homodimers (ISGF1) for GAS-responsive genes |
| STAT2 | Forms heterodimer with STAT1 for ISRE-responsive genes |
| IRF9 | Partners with STAT1/STAT2 to form ISGF3 complex |

Downstream Effectors

IFNAR2 signaling activates numerous downstream pathways beyond STATs:

• PI3K-AKT: Promotes cell survival
• MAPK/ERK: Regulates proliferation and differentiation
• NF-κB: Mediates inflammatory gene expression
• IRF7: Drives type I interferon "amplification loop"

Negative Regulation

IFNAR2 signaling is tightly controlled by several mechanisms:

• SOCS1/SOCS3: Suppressors of cytokine signaling inhibit JAK activity
• PIAS: Protein inhibitors of activated STATs block DNA binding
• PTPs: Protein tyrosine phosphatases dephosphorylate STATs
• Protein degradation:Ubiquitin-mediated turnover of signaling components

Therapeutic Implications

JAK Inhibitors

Several JAK inhibitors have shown promise in neurodegenerative disease models:

| Drug | Target | Stage | Key Findings |
|------|--------|-------|--------------|
| Ruxolitinib | JAK1/2 | Preclinical | Reduces microglial activation, protects neurons[@dhareshwari2021] |
| Baricitinib | JAK1/2 | Preclinical | Improves cognitive function in AD models |
| Tofacitinib | JAK1/3 | Research | Modulates neuroinflammation |

Soluble IFNAR2

Recombinant sIFNAR2 acts as a natural interceptor of type I interferons, potentially providing a more targeted approach than JAK inhibitors. This strategy is particularly appealing for conditions characterized by elevated IFN-I, such as SLE and certain viral encephalitides[@matic2023].

Therapeutic Challenges

Several challenges must be addressed:

• BBB Delivery: Ensuring CNS penetration of therapeutic agents
• Timing: Determining optimal intervention point in disease progression
• Specificity: Achieving selective modulation without compromising antiviral immunity
• Biomarkers: Identifying patient populations most likely to benefit

Animal Models

Genetic Models

• Ifnar2 knockout mice: Viable but display enhanced susceptibility to viral infections
• Conditional KO models: Brain-specific deletion reveals role in neuroinflammation
• Transgenic models: Neuronal overexpression of IFN-β produces neurodegeneration

Disease Models

• 5xFAD mice: IFN-I signatures correlate with amyloid burden
• α-Synuclein transgenic mice: IFN-I blockade reduces pathology
• MPTP models: JAK inhibitors protect dopaminergic neurons

Research Directions

Emerging Areas

• Single-cell RNAseq: Characterizing IFN-I responses in specific cell types
• Spatial transcriptomics: Mapping IFN-signaling in AD/PD brain
• Biomarker development: Circulating IFNAR2 as disease marker
• Gene therapy: AAV-mediated delivery of dominant-negative IFNAR2

Clinical Trials

Several trials are investigating JAK inhibitors in neurodegenerative diseases:

• NCT04592862: Baricitinib in AD (completed)
• NCT04387747: Ruxolitinib in PD (ongoing)
• Various trials in MS continue to evaluate IFN-β response predictors

Cross-Links

• [JAK-STAT Signaling](/mechanisms/jak-stat-signaling-neurodegeneration)
• [Microglia in Neuroinflammation](/cell-types/microglia-neuroinflammation)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Type I Interferon Response](/mechanisms/type-i-interferon-response)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving IFNAR2 — Interferon Alpha Receptor 2 discovered through SciDEX knowledge graph analysis: